Compare SVRA & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRA | HQH |
|---|---|---|
| Founded | 2007 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | SVRA | HQH |
|---|---|---|
| Price | $5.58 | $19.00 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 183.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $14.31 |
| 52 Week High | $7.01 | $17.94 |
| Indicator | SVRA | HQH |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 52.03 |
| Support Level | $5.47 | $18.39 |
| Resistance Level | $6.64 | $19.14 |
| Average True Range (ATR) | 0.35 | 0.34 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 7.60 | 64.47 |
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.